Abstract
We conducted a study to understand the genetic effect of ERCC1 and RRM1 on the chemotherapy response and clinical outcome of Non-Small Cell Lung Cancer (NSCLC). The relative cDNA quantification for ERCC1 and RRM1 was conducted using a fluorescence-based real-time detection method among 294 NSCLC patients. Compared with the internal reference gene β-action, the median levels of ERCC1 and RRM1 expression were 2.43×10(-2) and 0.11×10(-2), respectively. Our study showed response to platinum-containing regimen chemotherapy was high in those with high ERCC1 expression, and the OR (95% CI) were 1.73(1.06-2.81). An apparently high response to chemotherapy was decreased when patients were carrying both high expression of ERCC1 and RRM1, with OR (95% CI) of 2.57(1.21-4.90). Patients with high expression of ERCC1 were associated with a longer OS by multivariate Cox proportional hazards model. Moreover, those carrying both high levels of ERCC1 and RRM1 were seem to have a longer OS when compared with those with low expression (HR=0.31, 95% CI=0.13-0.62 for OS). This observation could be used in personalized chemotherapy, increase the response rate and prolonged survival time, and could encourage to explore the predictive value of other genes.
Highlights
Lung cancer is a common malignancy with highincidence and mortality, which is reported to be the highest fate cancer in China and worldwide.[1]
Individualized chemotherapy according to reliable molecular prognostic and predictive markers may play an important role in the clinical outcome of cancer patients
The present study suggests that high expression of RRM1 was associated with longer survival time and better response to chemotherapy when compared with low expression
Summary
Lung cancer is a common malignancy with highincidence and mortality, which is reported to be the highest fate cancer in China and worldwide.[1] Nonsmall cell lung cancer accounted for almost 85% of all cases, and most of them have been in advanced stage when they were diagnosed. 1-3: Respiratory and Critical Care Medicine, the First Affiliated Hospital, Henan University of Science and Technology, Luoyang, China
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
